Best Genomics Companies in Los Angeles, United States
The 32 best Genomics companies in Los Angeles, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: C3J Therapeutics.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Los Angeles
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | C3J Therapeutics Developing phage therapeutics to combat antibiotic-resistant bacterial infections | $124M | 118 mo ago | 60 | — | — | — | — |
| 2 | Octant Provider of human cell interaction platform for drug discovery | $115M | 54 mo ago | 65 65 → 68 (+5%) | — | WebflowApple iCloud MailGoogle Workspace+11 | 52 patents Patents concentrated in chemistry & materials | — |
| 3 | Seed Developer of synbiotics for simulating gut microbiome | $41M | 66 mo ago | 179 | Raja Dhir Co-Founder & Co-CEO | Amazon WebstoreTurbopackstyled-components+42 | 38 patents Genetically engineered herbicide‑resistant sorghum and alfalfa via ACC pathway mutations | — |
| 4 | Transplant Genomics Developer of molecular diagnostic tests to detect early signs of graft injury | $21M | 98 mo ago | 11 | Stanley Rose CEO & President | WordPress Block EditorWordPressMySQL+18 | 15 patents Non‑invasive cfDNA diagnostics for organ transplant rejection monitoring | — |
| 5 | Fount Provider of jet lag prevention and recovery kits for travelers. | $12M | 43 mo ago | 21 | Andrew Herr Founder & CEO | — | — | — |
| 6 | Tute Genomics Cloud-based solution for precision, genome guided medicine | $9M | 132 mo ago | 24 | — | — | — | — |
| 7 | MicrobeDx Provider of the solutions for the detection of antibiotic susceptibility in urinary tract infections | $6M | 70 mo ago | 3 | — | — | 61 patents Rapid nucleic-acid based microbial detection and antimicrobial susceptibility testing technologies | — |
| 8 | Sequencing.com Developer of technology that integrates genetic data into software applications | $5M | 48 mo ago | 25 | — | Cart FunctionalityApple iCloud MailGoogle Workspace+26 | — | — |
| 9 | DxTerity Provider of a direct-to-consumer, non-clinical genetic tests | $4M | 142 mo ago | 37 | Bob Terbrueggen President and CEO | — | — | — |
| 10 | MyoGene Bio Manufacturer of devices for muscular dystrophy treatment 8Talent top 38%Funding top 45%Global bottom 29%Market bottom 10% All 4 signals ▾Talenttop 38% Fundingtop 45% Globalbottom 29% Marketbottom 10% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $3.2M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 8/100 | $3M | 12 mo ago | 3 | April Pyle Co-Founder | — | — | — |
| 11 | Molecular Instruments Provider and developer of molecular instruments for drug development | $2M | 26 mo ago | 28 | — | Cart FunctionalityWixSentry+11 | — | — |
| 12 | Cytomag Microfluidic systems for cell isolation and analysis primarily for the detection and analysis of circulating… | $2M | 145 mo ago | — | Matthew Kerby Founder & CEO | — | — | — |
| 13 | Maven Biotech Develops label free internal reflection ellipsometry analysis systems | $2M | 193 mo ago | — | William Rassman Founder & CEO | — | — | — |
| 14 | SeqOnce Biosciences Provider of products & services for DNA and RNA Next Generation Sequencing sample preparation | $2M | 24 mo ago | 17 | — | — | — | — |
| 15 | EntroGen Molecular diagnostic solutions for oncology, hematology, automation, reagents, and software | $286K | 159 mo ago | 20 | — | WordPressMySQLPHP+23 | — | — |
| 16 | OncoBox Tailored cancer therapy selection through deep molecular profiling for each patient | $120K | 112 mo ago | 4 | Andrew Garazha Co-Founder & CEO | — | — | — |
Top 12 Genomics companies in Los Angeles
#1
Seed · Los Angeles, California · founded 2020 · 3 employees$3.2Mraised▾
Manufacturer of devices for muscular dystrophy treatment
- Nov 2025Seed$400K
- May 2025Grant (prize money)$1.3M
- Sep 2024Grant (prize money)$110K
- May 2023Seed—
#2
Series B · Los Angeles, California · founded 2017 · 65 employees$115Mraised▾
Provider of human cell interaction platform for drug discovery. The platform GPCR features synthetic biology, gene editing, genome engineering applications, next-generation sequencing method, and computational tools to simultaneously measure the activity of receptor pathways in human cells. These big datasets will be able to develop and apply machine learning methods to engineer small molecules which react with multiple receptors, enabling the discovery of drugs for complex diseases.
- Apr 2022Series B$80M
- Apr 2021Grant (prize money)$316.6K
- May 2020Series A$30M
- May 2020Grant (prize money)$246.9K
#3
Seed · Los Angeles, California · founded 2014 · 17 employees$1.9Mraised▾
SeqOnce Biosciences is developing technologies and providing products & services for DNA and RNA Next Generation Sequencing sample preparation. Its products include kits for next generation sample preparation including ProntoSeq- a suite of Library Preparation kits for Illumina NGS Platforms; Pronto-Seq- Rapid DNA-seq Kits (WGS, ChIP-seq, Bisulfite-seq); Pronto-Seq- Library Prep Kits (mid-2017) (Single Cell WGA, cDNA, PCR-Free WGS). The company also provides NGS sample preparation service using its novel sample preparation technology.
- Oct 2024Seed$881.8K
- Oct 2018Seed—
- Apr 2018Seed$1M
#4
Series D · Los Angeles, California · founded 2006 · 60 employees$124.5Mraised▾
Developing phage therapeutics to combat antibiotic-resistant bacterial infections. This clinical-stage biotechnology company focuses on pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections. Addressing the global challenge of antibiotic resistance, the company utilizes its proprietary bacteriophage-based technology. The company discovers natural phages and harnesses their power through synthetic biology and engineering. In-house formulation development allows tailoring of drug products to specific indications. The company has in-house cGMP drug manufacturing suites and a Quality Unit, enabling the production, testing, and release of clinical trial material. This biotech company is dedicated to providing solutions for the post-antibiotic era, where common infections can be life-threatening, and broad-spectrum antibiotics disrupt the human microbiome.
- Dec 2016Series D$19M
- Dec 2015Grant (prize money)$567.8K
- Mar 2014Series D$60.5M
- Feb 2012Series B$30M
#5
Funding Raised · Los Angeles, California · founded 2018 · 28 employees$2.1Mraised▾
Provider and developer of molecular instruments for drug development. The company has designed a molecular hybridization instrument that assists academic researchers with, drug development and clinical diagnosis. The device has features for a hybridization chain reaction, qHCR Imaging, flow cytometry, northern blots, and more.
- Sep 2024Grant (prize money)$905.9K
- Apr 2021Grant (prize money)$1.1M
#6
Series A · Los Angeles, California · founded 2018 · 21 employees$12Mraised▾
{}
- Mar 2023Series A$12M
#7
Series A · Los Angeles, California · founded 2016 · 179 employees$40.6Mraised▾
Developer synbiotics for simulating the gut microbiome. The company metabolomic sequencing and has developed a proprietary screening platform for the screening of host mechanistic pathways. The company claims that the probiotics developed to contain the strains having GRAS and/or QPS (Qualified Presumption of Safety) status. The strains have shown improvements in multiple markers of gastrointestinal health, cardiovascular health, and dermatological health.
- Apr 2021Series A$40.6M
- Jun 2018Series A—
#8
Acquired · Los Angeles, California · founded 2013 · 11 employees$20.6Mraised▾
Developer of molecular diagnostic tests to detect early signs of graft injury. The company has developed TruGraf is a non-invasive test that measures differentially-expressed genes in the blood of transplant recipients to identify patients who are likely to be adequately immunosuppressed by using genomic biomarkers.
- Aug 2018Series A$8M
- Apr 2017Series A$3.2M
- Feb 2017Series A$1.7M
- May 2016Series A$530K
#9
Series A · Los Angeles, California · founded 2014 · 25 employees$5Mraised▾
Developer of technology that integrates genetic data into software applications. Its patent pending Real-Time Personalization (RTP) technology converts genetic code into easy-to-use software code which then turns genetic data into useful information. It also provides free, unlimited storage of genetic data as well as unique tools and free apps.
- Nov 2022Series A$5M
#10
Series A · Los Angeles, California · founded 2015 · 3 employees$6.2Mraised▾
MicrobeDx develops solutions for the detection of antibiotic susceptibility in urinary tract infections. Its platform uses hybridization and capture of ribosomal RNA, which allows identification of bacterial species without the use of PCR, and combines it with phenotypic testing of antibiotic susceptibility. The company claims that species identification can be obtained in 30-45 minutes, and antibiotic susceptibility within 3 hours.
- Dec 2020Series A$300K
- Mar 2019Series A$3M
- Mar 2018Grant (prize money)$300K
- Jan 2018Series A$2.5M
#11
Acqui-Hired · Los Angeles, California · founded 2012 · 24 employees$8.9Mraised▾
Tute Genomics offers clinical-grade web-based application, powered by machine learning algorithms that allow researchers and clinicians to analyze, utilize, and interpret human genomes data for scientific discovery and individualized treatment. The company’s platform also supports disease gene finding and biomarker discovery, as well as provides machine intelligence, genome management, data filtration for streamlined output, and association analysis. Its platform serves pharmaceuticals and biotechnology companies, genetics laboratories, and research centers.
- Oct 2015Series A$868.5K
- Jun 2015Series A$3.9M
- Dec 2014Series A$2.3M
- Dec 2013Seed$300K
#12
Series A · Los Angeles, California · founded 2006 · 37 employees$3.6Mraised▾
Provider of direct-to-consumer, non-clinical genetic tests. It uses RT-PCR and DxTerity's proprietary DxDirect chemistry for the development of assay, DxDirect, a technique for analysis of gene signatures that combines chemical ligation process, NEAT, and sample stabilization system, DxCollect. Using DxTerity's genomics platform, fingerstick blood can be safely collected and shipped to DxTerity via US mail for non-clinical analysis.
- Dec 2014Series A$100K
- Feb 2012Series A$2.6M
- Sep 2011Grant (prize money)$167K
- Sep 2011Grant (prize money)$167K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in the United States
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,110 United States-affiliated papers.
- Harvard University633
- Broad Institute433
- Howard Hughes Medical Institute318
- Stanford University287
- Johns Hopkins University287
- Gene83→532
- Transcriptome25→436
- Genome117→419
- Disease6→218
- Immune system11→219
- Disease17→407
- Immune system4→266
- Gene38→281
- Transcriptome13→238
- Biomarker2→208
- Disease27→311
- Immune system6→152
- Cancer17→130
- Clinical trial4→111
- Biomarker2→92
Where bioinformatics is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing bioinformatics patents in the United States
United States bioinformatics patent filing is accelerating — 246 filings from 64 assignees (2016–2025), led by Edico Genome, Illumina, UNIV Washington; annual filings 22→23.
- Edico Genome129
- Illumina60
- UNIV Washington18
- Nantomics9
- Genomsys7
- Baluch Mohamed Khoso7
- Microsoft6
- Contamination Source Identificat6
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.